Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Reid, DM; Devogelaer, JP; Saag, K; Roux, C; Lau, CS; Reginster, JY; Papanastasiou, P; Ferreira, A; Hartl, F; Fashola, T; Mesenbrink, P; Sambrook, PN; Perrelet, Romain; HORIZON, investigators (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373(9671), pp. 1253-1263. London: Elsevier 10.1016/S0140-6736(09)60250-6

Full text not available from this repository. (Request a copy)

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis
UniBE Contributor:	Perrelet, Romain
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0140-6736
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:13
Last Modified:	05 Dec 2022 14:22
Publisher DOI:	10.1016/S0140-6736(09)60250-6
Web of Science ID:	000265146300028
URI:	https://boris.unibe.ch/id/eprint/32401 (FactScience: 197558)